Breaking News

Thursday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
LH LabCorp $143.32 -4.795 (-3.24%) 08:27 12/06/18 12/06 08:27 12/06/18 08:27 Recommendations	LabCorp analyst commentary at KeyBanc » LabCorp price target… LabCorp price target lowered to $165 from $210 at KeyBanc. KeyBanc analyst Donald Hooker lowered his price target for LabCorp to $165 from $210, while reiterating an Overweight rating on the shares. The analyst recommends LabCorp on relative valuation given the strength of its Covance Drug Development segment. However, the situation has deteriorated for its legacy lab business, he contended. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Over a week ago
VZ Verizon $58.25 -2.01 (-3.34%) , COST Costco $229.44 -1.85 (-0.80%) … 10:32 12/03/18 12/03 10:32 12/03/18 10:32 Downgrade	On The Fly: Top five analyst downgrades » Catch up on today's… Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Verizon (VZ) downgraded to Neutral from Overweight at JPMorgan with analyst Philip Cusick saying that as much as he likes Verizon's "consistent and improving execution," the combination of a new management team and reporting lines with the stock's 17% year-to-date increase make the risk/reward less compelling than peers AT&T (T) and Comcast (CMCSA). 2. Costco (COST) downgraded to Neutral from Buy at Citi with analyst Kate McShane saying she sees "more headwinds than tailwinds likely in 2019" for Costco. 3. Tractor Supply (TSCO) downgraded to Perform from Outperform at Oppenheimer with analyst Brian Nagel saying he views lower oil prices as a risk for the company. 4. LabCorp (LH) downgraded to Hold from Buy at Craig-Hallum and to Neutral from Buy at BofA/Merrill. 5. Quest Diagnostics (DGX) downgraded to Neutral from Buy at BofA/Merrill with analyst Derik de Bruin citing the cut in FY18 guidance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here. VZ Verizon $58.25 -2.01 (-3.34%) COST Costco $229.44 -1.85 (-0.80%) TSCO Tractor Supply $94.82 -0.33 (-0.35%) LH LabCorp $145.44 -0.09 (-0.06%) DGX Quest Diagnostics $89.20 0.62 (0.70%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	03 Dec 03 Dec 03 Dec 04 Dec 06 Dec
LH LabCorp $145.53 -16.25 (-10.04%) 09:06 12/03/18 12/03 09:06 12/03/18 09:06 Recommendations	LabCorp analyst commentary at William Blair » LabCorp shares… LabCorp shares overreacted to guidance reduction, says William Blair. William Blair analyst Matt Larew says LabCorp shares overreacted to Friday's guidance reduction. The company's long-term story remains intact and selloff creates an attractive long-term entry point, Larew tells investors in a research note. He continues to believe LabCorp's efforts to build scale and diversify its contract research organization business by leveraging its broad patient access will lead to higher revenue growth than was the case when Covance was independent. He keeps an Outperform rating on the shares. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
LH LabCorp $145.53 -16.25 (-10.04%) , UNH UnitedHealth $281.21 -0.35 (-0.12%) 08:47 12/03/18 12/03 08:47 12/03/18 08:47 Downgrade	LabCorp, UnitedHealth rating change » LabCorp downgraded to… LabCorp downgraded to Hold at Craig-Hallum on headwinds ahead. As previously reported, Craig-Hallum analyst Kevin Ellich downgraded LabCorp (LH) to Hold from Buy as he believes volume and reimbursement headwinds will intensify in 2019 keeping a lid on the stock. While lower 23andMe volume is understandable due to lower than forecast Black Friday and Cyber Monday sales, the analyst is concerned about lower volume from hospitals, which might be attributable to hospitals keeping more testing in-house, especially with physician-owned practices. Given the lowered 2018 outlook and increased pressure in 2019, Ellich also reduced his estimates and lowered his price target on the shares to $152 from $193. Overall, the analyst argues that lost UnitedHealth (UNH) exclusivity starts snowball effect as "Winter is coming" for LabCorp with lowered FY18 guidance. LH LabCorp $145.53 -16.25 (-10.04%) UNH UnitedHealth $281.21 -0.35 (-0.12%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
LH LabCorp $145.53 -16.25 (-10.04%) 08:32 12/03/18 12/03 08:32 12/03/18 08:32 Recommendations	LabCorp analyst commentary at SunTrust » LabCorp price target… LabCorp price target lowered to $175 from $220 at SunTrust. SunTrust analyst David MacDonald lowered his price target on LabCorp to $175 after the company cut its FY18 guidance last week amid "slower growth in referred direct-to-consumer genetic testing" along with lower hospital and health system referrals. The analyst also expects the company's 2019 to be a "bit of a grind", but sees its long-term positive lab industry fundamentals remaining "intact" and maintains his Buy rating. MacDonals adds that the incremental pressure related to "Protecting Access to Medicare Act" legislation "likely drives share gain opportunity and further accelerates potential M&A" for LabCorp. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

LH LabCorp 07:57 12/03/18 12/03 07:57 12/03/18 07:57 Recommendations	LabCorp analyst commentary at Barclays » Barclays cuts LabCorp… Barclays cuts LabCorp target to $165, removes Top Pick designation. Barclays analyst Jack Meehan lowered his price target for LabCorp to $165 and $205 and removed the stock's Top Pick designation after the company on Friday lowered its Q4 outlook. The magnitude of the reduction so shortly after the company reduced guidance with Q3 earnings is a disappointing surprise, Meehan tells investors in a research note. The analyst, however, reiterates an Overweight rating on LabCorp saying several of LabCorp's issues are now "in the baseline." 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
LH LabCorp $145.53 -16.25 (-10.04%) 07:49 12/03/18 12/03 07:49 12/03/18 07:49 Recommendations	LabCorp analyst commentary at Canaccord » LabCorp downside move on… LabCorp downside move on lowered guidance overdone, says Canaccord. Canaccord analyst Mark Massaro noted LabCorp surprised by lowering its Q4 top and bottom line guidance, but he believes the downside move of roughly 10% is overdone. He said the lowered guidance was mainly due to revenue accrual accounting, though he also believes the company is losing market share. Massaro maintained his Hold rating and lowered his price target to $155 from $162 on LabCorp shares. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
LH LabCorp $145.53 -16.25 (-10.04%) 07:11 12/03/18 12/03 07:11 12/03/18 07:11 Downgrade	LabCorp rating change at BofA/Merrill » LabCorp downgraded to… LabCorp downgraded to Neutral from Buy at BofA/Merrill. BofA/Merrill analyst Derik de Bruin downgraded LabCorp to Neutral from Buy and reduced its price target to $152 from $191 following the cut in FY18 guidance. de Bruin does not believe the root causes for the weakness are well understood and fears there could be further reductions going forward given the lack of visibility. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
LH LabCorp $145.53 -16.25 (-10.04%) 07:04 12/03/18 12/03 07:04 12/03/18 07:04 Downgrade	LabCorp rating change at Craig-Hallum » LabCorp downgraded to… LabCorp downgraded to Hold from Buy at Craig-Hallum 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
LH LabCorp $147.00 -14.78 (-9.14%) , DGX Quest Diagnostics $85.88 -2.06 (-2.34%) … 09:51 11/30/18 11/30 09:51 11/30/18 09:51 Recommendations	LabCorp, Quest Diagnostics, UnitedHealth analyst commentary at Piper Jaffray » LabCorp selloff brings… LabCorp selloff brings long-term buying opportunity, says Piper Jaffray. LabCorp (LH) this morning followed Quest Diagnostics' (DGX) lead and lowered its guidance due to lower volumes in the Diagnostics business, Piper Jaffray analyst William Quirk tells investors in a research note. The analyst, however, believes the volume softness is "largely short-term" when excluding UnitedHealth (UNH) and provides a long-term buying opportunity. He keeps an Overweight rating on LabCorp but lowered his price target for the shares to $177 from $180 to "reflect this setback." LH LabCorp $147.00 -14.78 (-9.14%) DGX Quest Diagnostics $85.88 -2.06 (-2.34%) UNH UnitedHealth $282.81 1.25 (0.44%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	03 Dec 04 Dec

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial